Lv1
40 积分 2024-12-05 加入
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor
1个月前
已完结
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC Degrader
3个月前
已完结
Biopharma dealmaking in 2024
3个月前
已完结
Top 20 biopharma deals of 2023
3个月前
已完结
China’s increasing flow of innovative assets into big pharma R&D pipelines
3个月前
已完结
Cadherin-17: a promising target for therapy of HCC
4个月前
已完结
The company landscape for artificial intelligence in large-molecule drug discovery
4个月前
已完结
The landscape for radioligand therapies in oncology
5个月前
已完结
Radiotheranostic landscape: A review of clinical and preclinical development
6个月前
已完结
New guise ADCs couple antibodies to degraders
8个月前
已完结
皖公网安备34019202002308
